Spero Therapeutics, Inc. Deferred Revenue
Spero Therapeutics, Inc. (SPRO) had Deferred Revenue of $0 as of 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2026-03-26
- 2025-12-31: Deferred Revenue, Current $0.00.
- 2025-09-30: Deferred Revenue, Current $0.00.
- 2025-06-30: Deferred Revenue, Current $0.00.
- 2025-03-31: Deferred Revenue, Current $0.00.
| Period end | Deferred Revenue, Current | Deferred Revenue, Current as first filed |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-26 | |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $368.00K 10-K · filed 2026-03-26 | |
| 2024-09-30 | $788.00K 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $3.66M 10-Q · filed 2024-08-05 | |
| 2024-03-31 | $2.87M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $2.13M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $13.87M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $8.71M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $11.85M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $4.15M 10-K · filed 2024-03-13 | $10.37M 10-K · filed 2023-03-30 |
| 2022-09-30 | $3.73M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $2.36M 10-Q · filed 2022-08-10 | |
| 2022-03-31 | $2.09M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $1.86M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $1.70M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $1.18M 10-Q · filed 2021-08-05 | |
| 2020-12-31 | $0.00 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |